A Nanoparticle Formulation to Sensitise Cancer Cells to Conventional Radio or Chemotherapy

Abstract/Technology Overview

Cancer remains a leading disease burden on global society. Radiotherapy and chemotherapy are two of the most common approaches to treating cancers.

Radiotherapy contributes to about 40% of cures, but advances in radiotherapy have been limited due to engineering constraints.

Chemotherapy is used extensively in treating metastatic cancer where the cancer has spread to other parts of the body. However, for many cancers it only prolongs survival by months. Moreover, due to its highly toxic nature, many patients struggle to complete the therapeutic regime.

In both cases, a higher dose of the therapeutic agent is needed to treat resistant cancer cells, which further aggravates the side-effects associated with these treatments leading to poor adherence and outcomes. There is a clear need for a new approach to improving cancer therapy. One approach is to exploit and manipulate the tumor's microenvironment and its response to current treatments.

Technology Features, Specifications and Advantages

The team is developing nanoparticle formulations that can manipulate a cancer cell’s propensity to be affected by conventional treatments such as radio or chemotherapy.

The underlying mechanism preferentially impacts cancer cells that are difficult to treat and act as negative prognostic factors. These formulations can halve the amount of radiation required to treat radioresistant cells. The technology has the potential to have profound impact on treatment efficacy and minimisation of side-effects; improving mortality rates and quality of life for patients.

Potential Applications

The technology, a nanoparticle formulation to sensitise cancer cells to conventional radio or chemotherapy, has the potential for application in multiple markets.

It could be applied in the field of biotechnology, the medical device industry, and pharmaceutical industries with applications in cancer therapy such as radio and/or chemotherapy treatments.

Customer Benefit

  • Biocompatible
  • Can reduce the required chemo/radiation dose to achieve required therapeutic effect
  • Could reduce patient drop-out by reducing side-effects and improve treatment outcomes
  • Increased quality of life and reduced mortality rates

Contact Person

Viraj Perera


UniSA Ventures Pty Ltd

Technology Category
  • Pharmaceuticals & Therapeutics
Technology Status
  • Available for Licensing
Technology Readiness Level
  • TRL 3

cancer, cancer therapy, radiotherapy, chemotherapy